What does GKB Ophthalmics do?

GKB Ophthalmics Ltd is a Micro Cap company in the Healthcare Services industry, established in 1981, specializing in ophthalmic products. As of March 2025, it reported net sales of 31 Cr and a net loss of 4 Cr, with a market cap of Rs 39 Cr.

Overview:<BR>GKB Ophthalmics Ltd is a company operating in the Healthcare Services industry, categorized as a Micro Cap.<BR><BR>History:<BR>Incorporated in December 1981, GKB Ophthalmics was granted a license as a 100% Export Oriented Unit (EOU) in 1982. The company reported its latest quarterly results for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 31 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -4 Cr (Quarterly Results - Mar 2025) <BR>Market cap: Rs 39 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.01 <BR>Return on Equity: -13.55% <BR>Price to Book: 0.71<BR><BR>Contact Details:<BR>Address: 16-A, Tivim Industrial Estate Mapusa Goa : 403526 <BR>Tel: 91-832-2257253/6714444 <BR>Email: investor.grievance@gkb.net <BR>Website: http://www.gkb.net

Who are in the management team of GKB Ophthalmics?

As of March 2022, the management team of GKB Ophthalmics includes K G Gupta (Chairman/Executive Director), Vikram Gupta (Non-Executive Director), Subhash Redkar (Executive Director), and three Independent Non-Executive Directors: Anil Palekar, Shashi Kumar Katreddi, and Purushottam Mantri. They collectively contribute to the company's governance and strategic direction.

As of March 2022, the management team of GKB Ophthalmics includes the following individuals:<BR><BR>1. K G Gupta - Chairman / Executive Director<BR>2. Vikram Gupta - Non Executive Director<BR>3. Subhash Redkar - Executive Director<BR>4. Anil Palekar - Independent Non Executive Director<BR>5. Shashi Kumar Katreddi - Independent Non Executive Director<BR>6. Purushottam Mantri - Independent Non Executive Director<BR><BR>These members play various roles within the company, contributing to its governance and strategic direction.

Has GKB Ophthalmics declared dividend?

GKB Ophthalmics Ltd has declared a 12% dividend, amounting to 1.2000 per share, with an ex-date of September 21, 2010. However, total returns over various periods show negative performance in the short term, and the dividend yield is 0%, indicating minimal impact on shareholder returns.

GKB Ophthalmics Ltd has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2000<BR>- Ex-date: Sep-21-2010<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>Over the 6-month period, the price return was -24.87%, the dividend return was 0%, resulting in a total return of -24.87%.<BR><BR>For the 1-year period, the price return was -13.74%, the dividend return was 0%, leading to a total return of -13.74%.<BR><BR>In the 2-year period, the price return was -15.2%, the dividend return was 0%, which resulted in a total return of -15.2%.<BR><BR>During the 3-year period, the price return was 0%, the dividend return was 0%, yielding a total return of 0.0%.<BR><BR>For the 4-year period, the price return was 12.49%, the dividend return was 0%, culminating in a total return of 12.49%.<BR><BR>In the 5-year period, the price return was 23.2%, the dividend return was 0%, resulting in a total return of 23.2%.<BR><BR>Overall, while GKB Ophthalmics Ltd has declared a dividend, the total returns over various periods indicate a negative performance in the short term, with only modest gains in the longer term. The absence of dividend yield suggests that the declared dividend has not significantly impacted shareholder returns.

Who are the peers of the GKB Ophthalmics?

GKB Ophthalmics' peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Amkay Products, Transgene Biotek, Shree Pacetronix, and Samsrita Labs. GKB has below-average management risk and a 1-year return of -13.45%, better than Amkay Products but worse than Poly Medicure, which leads with a 24.29% return.

Peers: The peers of GKB Ophthalmics are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Amkay Products, Transgene Biotek, Shree Pacetronix, and Samsrita Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Amkay Products, and Shree Pacetronix, and the rest. Below Average management risk is seen at GKB Ophthalmics and Adeshwar Meditex. Growth ratings show Excellent at Dr Lal Pathlabs, Average at Poly Medicure, Indegene, and Shree Pacetronix, while Below Average is noted for Syngene Intl., Vijaya Diagnost., GKB Ophthalmics, Amkay Products, and Adeshwar Meditex, and the rest. Capital Structure is Excellent for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and the rest, while Good is noted for GKB Ophthalmics and Shree Pacetronix, and Average for Amkay Products.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.29%, while Amkay Products has the lowest at -34.33%. GKB Ophthalmics' 1-year return is -13.45%, which is higher than Amkay Products but lower than Poly Medicure. Additionally, the peers with negative six-month returns include Syngene Intl., Amkay Products, Transgene Biotek, Shree Pacetronix, and Adeshwar Meditex.

Is GKB Ophthalmics overvalued or undervalued?

As of August 14, 2023, GKB Ophthalmics is considered undervalued with a risky valuation grade, reflected by its negative PE ratio of -5.36 and EV to EBITDA of -13.84, especially when compared to peers like Hindustan Unilever and Nestle India, and its stock has underperformed the Sensex with a year-to-date return of -24.04%.

As of 14 August 2023, the valuation grade for GKB Ophthalmics has moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently considered undervalued, particularly given its negative PE ratio of -5.36 and an EV to EBITDA ratio of -13.84, which highlight substantial financial distress. Additionally, the Price to Book Value stands at 0.73, suggesting that the market values the company below its book value.<BR><BR>In comparison to its peers, GKB Ophthalmics shows stark contrasts; for instance, Hindustan Unilever has a PE ratio of 53.88 and an EV to EBITDA of 37.14, while Nestle India exhibits even higher figures with a PE of 75.2 and an EV to EBITDA of 49.57. These comparisons underscore the challenges faced by GKB Ophthalmics, as it operates in a sector where competitors are significantly more valued. Furthermore, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -24.04% compared to the Sensex's 5.63%, reinforcing the notion of its undervaluation amidst broader market trends.

What is the technical trend for GKB Ophthalmics?

As of May 23, 2025, GKB Ophthalmics is in a mildly bearish trend, with daily moving averages and Bollinger Bands indicating bearish conditions, despite some mildly bullish signals from the MACD and Dow Theory.

As of 23 May 2025, the technical trend for GKB Ophthalmics has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the Bollinger Bands showing bearish conditions on both weekly and monthly time frames. The MACD on a weekly basis is mildly bullish, which contrasts with the monthly bearish signal, while the RSI shows no signal on the weekly but is bullish on the monthly. Dow Theory supports a mildly bullish stance on both weekly and monthly time frames, but overall, the bearish indicators dominate the current outlook.

Who are the top shareholders of the GKB Ophthalmics?

The top shareholders of GKB Ophthalmics include promoter Krishna Gopal Gupta with 17.91%, public shareholder Krishna Murari Gupta at 5.54%, and individual investors holding 37.36%. There are no pledged promoter holdings or mutual funds invested in the company.

The top shareholders of GKB Ophthalmics include the promoters, with Krishna Gopal Gupta holding the largest share at 17.91%. The highest public shareholder is Krishna Murari Gupta, who holds 5.54%. Additionally, individual investors collectively hold 37.36% of the company's shares. There is also one foreign institutional investor (FII) that holds 1.79% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

How big is GKB Ophthalmics?

As of 24th July, GKB Ophthalmics Ltd has a market capitalization of 38.00 Cr and reported Net Sales of 108.98 Cr with a Net Profit loss of 7.05 Cr over the latest four quarters. The balance sheet for March 2024 shows Shareholder's Funds of 59.77 Cr and Total Assets of 114.50 Cr.

As of 24th July, GKB Ophthalmics Ltd has a market capitalization of 38.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, GKB Ophthalmics reported Net Sales of 108.98 Cr. However, the company experienced a loss of 7.05 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 59.77 Cr and Total Assets of 114.50 Cr.

When is the next results date for GKB Ophthalmics?

GKB Ophthalmics will announce its results on 14 August 2025.

GKB Ophthalmics will declare its results on 14 August 2025.

Are GKB Ophthalmics latest results good or bad?

GKB Ophthalmics' latest results show strong quarterly sales and a significant profit increase, but concerns arise from a negative cash flow and low liquidity, leading to a 'Strong Sell' rating from MarketsMOJO. Overall, the financial health appears under pressure despite some positive growth indicators.

GKB Ophthalmics' latest results present a mixed picture. On one hand, the company achieved its highest quarterly net sales in the last five quarters, totaling Rs 32.31 crore, which is a positive sign of growth. Additionally, the consolidated net profit showed a significant improvement, increasing by 71.27% compared to the previous quarter, indicating a recovery from prior losses.<BR><BR>However, there are notable challenges as well. The company's annual operating cash flow has dropped to Rs -3.43 crore, the lowest in three years, which raises concerns about its cash generation capabilities. Furthermore, GKB Ophthalmics has reported its lowest cash and cash equivalents at Rs 13.82 crore in the last six half-year periods, reflecting weakened short-term liquidity. The stock is currently rated as a 'Strong Sell' by MarketsMOJO, suggesting that investor sentiment is cautious.<BR><BR>Overall, while there are some positive developments in sales and profit, the decline in cash flow and liquidity issues indicate that the company's financial health is under pressure.

How has been the historical performance of GKB Ophthalmics?

GKB Ophthalmics has seen revenue growth from INR 56.88 crore in March 2021 to INR 108.99 crore in March 2025, but has faced significant operating losses and negative cash flow, resulting in a profit after tax loss of -INR 7.26 crore in March 2025. Despite increasing total assets, the company's profitability has declined sharply in recent periods.

Answer:<BR>The historical performance of GKB Ophthalmics shows a fluctuating trend in revenue and profitability over the years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>GKB Ophthalmics has experienced a steady increase in net sales from INR 56.88 crore in March 2021 to INR 108.99 crore in March 2025. However, the company has faced rising total expenditures, which grew from INR 54.96 crore in March 2021 to INR 111.77 crore in March 2025, leading to operating losses. Operating profit (PBDIT) turned negative in March 2025 at -INR 1.45 crore, down from a positive INR 4.60 crore in March 2023. Profit before tax also declined significantly, reaching -INR 6.91 crore in March 2025, compared to a profit of INR 0.11 crore in March 2023. Consequently, the profit after tax showed a similar downward trend, resulting in a loss of -INR 7.26 crore in March 2025, compared to a small profit of INR 0.08 crore in March 2023. The company's total assets increased from INR 102.25 crore in March 2020 to INR 125.21 crore in March 2025, while total liabilities also rose from INR 102.25 crore to INR 125.21 crore during the same period. Cash flow from operating activities has been negative in the latest year at -INR 3.00 crore, indicating challenges in generating cash from core operations. Overall, GKB Ophthalmics has shown growth in sales but has struggled with profitability and cash flow in recent years.

Should I buy, sell or hold GKB Ophthalmics?

Which are the latest news on GKB Ophthalmics?

Why is GKB Ophthalmics falling/rising?

As of 03-Dec, GKB Ophthalmics Ltd's stock price is currently Rs. 50.94, reflecting a 6.21% decrease and a significant decline of 19.92% over the past four days. The stock is underperforming against the Sensex and has hit a new 52-week low, indicating a bearish trend despite increased delivery volume.

As of 03-Dec, GKB Ophthalmics Ltd's stock price is falling, currently at Rs. 50.94, which reflects a decrease of Rs. 3.37 or 6.21%. The stock has been on a downward trend, having lost 19.92% over the last four days and is significantly underperforming compared to the benchmark Sensex, which has only declined by 0.59% over the same week. <BR><BR>Today, the stock hit a new 52-week low of Rs. 49.15 and has shown high volatility, trading within a wide range of Rs. 6.52. Despite opening with a gain of 2.5% and reaching an intraday high of Rs. 55.67, it ultimately fell back to its current price. The stock is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. <BR><BR>Furthermore, while there has been a significant increase in delivery volume, rising by 343.7% against the 5-day average, the overall performance remains weak, with a year-to-date decline of 48.42%. This combination of factors contributes to the ongoing decline in GKB Ophthalmics' stock price.